ERNA Ernexa Therapeutics Inc.

NSD
$3.47

Ernexa Therapeutics Inc. (ERNA) is expected to report earnings on November 5, 2026, during market hours. The consensus earnings estimate is a loss of $3.84 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -13.3% since its last earnings release on August 6, 2026.

Ernexa Therapeutics Missed Consensus Estimates
Thursday, August 6, 2026 · 12:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · Market Hours
Earnings Whisper
-
vs ($3.84)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $4.27

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Ernexa Therapeutics Inc.

Ernexa Therapeutics is developing cell therapies for the treatment of advanced cancer and autoimmune disease. Ernexa Therapeutics, formerly known as Eterna Therapeutics, is based in CAMBRIDGE, Mass.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Charts powered in part by Lightweight Charts™ by TradingView.